| Species |
Human |
| Protein Construction |
Complement Factor D/CFD (Ile26-Ala253)
Accession # P00746-1 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Complement Factor D/CFD hFc Chimera, Human at 2μg/ml (100μl/Well) on the plate can bind Biotinylated AntiComplement Factor D Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
51.2 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 52-60 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Complement factor D is a serine protease essential for the activation of the alternative pathway and is expressed in the kidney, adipocytes, and macrophages. Factor D is found at relatively high levels in glomeruli suggesting that this component of the complement cascade could influence renal pathophysiology.Complement factor D or alternative pathway activation is needed to prevent spontaneous accumulation of C3 and IgM deposits within the mesangium. |
| Synonyms |
Adipsin; C3 convertase activator; Complement factor D; CFD; PFD; DF; ADN; FACTOR D; AMBP-1; EC 3.4.21; EC 3.4.21.46 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
